What is HC Wainwright's Estimate for GALT Q1 Earnings?

Key Points

• HC Wainwright analyst M. Keller forecasts Galectin Therapeutics' Q1 2026 EPS at ($0.06) and maintains a Buy rating with an $11.00 price target, also projecting Q2–Q4 EPS of ($0.07), ($0.09) and ($0.10) respectively.
• Galectin reported Q1 EPS of ($0.08), beating the consensus estimate of ($0.10) by $0.02.
• Insiders sold 204,000 shares worth $787,433 in the last 90 days, and insiders currently own 52.60% of the stock.

Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 EPS estimates for shares of Galectin Therapeutics in a note issued to investors on Tuesday, March 31st. HC Wainwright analyst M. Keller expects that the company will post earnings per share of ($0.06) for the quarter. HC Wainwright currently has a "Buy" rating and a $11.00 target price on the stock. The consensus estimate for Galectin Therapeutics' current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Galectin Therapeutics' Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.09) EPS and Q4 2026 earnings at ($0.10) EPS.

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last posted its earnings results on Monday, March 30th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.02.

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Galectin Therapeutics in a report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $11.00.

Galectin Therapeutics Stock Performance

NASDAQ:GALT opened at $2.68 on Thursday. Galectin Therapeutics has a one year low of $1.12 and a one year high of $7.13. The stock has a market cap of $172.78 million, a PE ratio of -5.58 and a beta of 1.03. The stock has a 50 day moving average price of $2.96 and a 200 day moving average price of $4.20.

Insider Activity

In related news, insider Khurram Jamil sold 25,499 shares of the business's stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $3.90, for a total transaction of $99,446.10. Following the sale, the insider owned 21,446 shares of the company's stock, valued at approximately $83,639.40. The trade was a 54.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Jack W. Callicutt sold 25,732 shares of the company's stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $3.90, for a total transaction of $100,354.80. Following the transaction, the chief financial officer owned 27,968 shares in the company, valued at $109,075.20. The trade was a 47.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 204,000 shares of company stock worth $787,433 in the last 90 days. 52.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Galectin Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE raised its holdings in shares of Galectin Therapeutics by 101.4% during the fourth quarter. Bank of America Corp DE now owns 38,358 shares of the company's stock worth $49,000 after purchasing an additional 19,316 shares during the period. XTX Topco Ltd increased its position in shares of Galectin Therapeutics by 226.6% during the 2nd quarter. XTX Topco Ltd now owns 42,805 shares of the company's stock valued at $90,000 after purchasing an additional 29,699 shares during the period. Marshall Wace LLP bought a new stake in shares of Galectin Therapeutics in the 2nd quarter worth $64,000. Vivaldi Capital Management LP grew its holdings in Galectin Therapeutics by 210.0% during the second quarter. Vivaldi Capital Management LP now owns 172,443 shares of the company's stock worth $364,000 after acquiring an additional 116,815 shares during the period. Finally, Jane Street Group LLC acquired a new stake in Galectin Therapeutics in the 2nd quarter valued at about $1,580,000. Institutional investors own 11.68% of the company's stock.

About Galectin Therapeutics

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company's lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.